Novartis | NVS - Betriebsaufwand

Aktienkurs
151.97
Täglich Wechseln
2.17 1.45%
Monatlich
1.49%
Jährlich
37.41%
Q2 Prognose
150.72




Betriebsaufwand Veränderung Datum
AbbVie USD 10.81B 13.45B 2025-12
Amgen USD 5.9B 773M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Bausch Health Companies USD 2.08B 113M 2025-12
Biogen USD 1.88B 81.4M 2025-09
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Canopy Growth CAD 87.2M 6.22M 2025-12
Corcept Therapeutics USD 197.64M 219K 2025-12
Drreddys Laboratories INR 72.94B 4.33B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Glaxosmithkline GBP 9.17B 1.4B 2025-12
J&J USD 17.44B 1.53B 2026-03
Merck USD 10.16B 558M 2025-12
Novartis USD 9.8B 61M 2025-12
Novartis USD 9.8B 23M 2025-12
Pacira USD 193.68M 27.32M 2025-12
Perrigo USD 1.03B 75.3M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Phibro Animal Health USD 332.36M 20.68M 2025-12
Prestige Brands USD 200.95M 6.51M 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 10.51B 1.21B 2025-12
Sanofi EUR 10.71B 1.32B 2025-12
Supernus Pharmaceuticals USD 197.75M 54.54M 2025-12
Zoetis USD 1.55B 3.85B 2025-12